Acute Myeloid Leukemia - AML

Acute myeloid leukemias (AMLs) are a heterogeneous group of disorders characterized by the clonal expansion of myeloid blasts (eg, undifferentiated myeloid precursors) in the peripheral blood, bone marrow, and/or other tissues, which results in impaired hematopoiesis and bone marrow failure.     AML is the most common acute leukemia in adults (~80% of leukemia cases) and accounts for the largest number of annual deaths from leukemia in the United States.   The median age at diagnosis is 67 years, and 54% of patients are diagnosed at 65 years of age or older.  Advances in the treatment of AML have led to significant improvement in outcomes for younger patients; however, prognosis in the elderly, in whom the majority of new cases occur, remains poor. 

The initial laboratory evaluation for AML includes blood chemistry, coagulation studies, and a CBC with a differential of white blood cells (WBCs). In addition to morphologic evaluation of the bone marrow, immunophenotypic, cytogenetic, and molecular genetic ancillary studies are standard of care and are necessary for accurate classification, risk stratification, and to guide therapy.

Tabs Content
Content Review: 
June 2019

Last Update: October 2019